Tag Archive for sales

Bravenly Global 700% Growth Year-Over-Year In 2022

Founded at the height of a global pandemic, Bravenly Global has grown exponentially over the past year. In its first full year (2021), sales reached $1 million; by the end of year two (2022), the company had grown 7-fold, to $8 million.
This new company was also voted #14 in the most recent Business For Home Top Direct Selling Companies 2023 poll, which included over 220 companies in the running, and was voted on by over 47,400 people globally.
CEO Aspen Emry shared:
“Bravenly comes from the guiding principle that, when we bravely step out in faith – when we ‘feel the fear and do it anyways’ – there is the promise that you’ll be strengthened and rewarded through this.
When each of us makes our own conscious decision to create the life that we deserve and are worthy of, at times we need to stare fear in the face and make a move towards it, because that’s when we can experience the most growth, which is key to joy.”
Over the last two decades, Aspen has risen from building a business in the field, to becoming a top producer, to being recruited as a key leader of the Field Development team of a

Read more...

Herbalife Revenue 2022 Down 10.3% To $5.2. Billion

Herbalife Nutrition Ltd. (NYSE: HLF) today reported financial results for the full year and fourth quarter ended December 31, 2022:
Highlights

Full year 2022 net sales of $5.2 billion, a 10.3% decrease compared to the full year 2021. On a constant currency basis1, net sales declined 5.4% compared to the prior year.

Full year 2022 reported diluted EPS of $3.23 and adjusted2 diluted EPS of $3.40, compared to full year 2021 reported and adjusted2 diluted EPS of $4.13 and $4.79, respectively.

Full year 2022 reported net income of $321.3 million and adjusted2 EBITDA of $694.5 million.

Fourth quarter 2022 net sales of $1.2 billion, a 10.4% decrease compared to the fourth quarter 2021. On a constant currency basis1, net sales declined 4.2% compared to the prior year period.

Fourth quarter 2022 reported diluted EPS of $0.55 and adjusted2 diluted EPS of $0.53, compared to fourth quarter 2021 reported and adjusted2 diluted EPS of $0.37 and $0.57, respectively.

Fourth quarter 2022 reported net income of $54.4 million and adjusted2 EBITDA of $130.7 million.

During the fourth quarter, the Company reduced its nominal debt level by approximately $60 million.

Given the rapidly shifting macroeconomic sentiment and backdrop, as well as increased volatility in the market, the Company is not providing FY 2023 guidance.
The Company’s previously announced Transformation

Read more...

LifeVantage Sales Up 2.8% To $53.7 Million

LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its second fiscal quarter ended December 31, 2022.
Second Quarter Fiscal 2023 Summary*:

Revenue of $53.7 million, an increase of 2.8% from the prior year period. Excluding the negative impact of foreign currency fluctuations, second quarter revenue was up approximately 7.4%;
Revenue in the Americas increased 14.4% including a 15.4% increase in the United States. Revenue in Asia/Pacific & Europe decreased 20.2% and was down approximately 7.0% excluding the negative impact of foreign currency fluctuations;
Total active accounts declined 8.6% from the prior year period to 149,000, reflecting a decline of 7.1% in the Americas and a 12.0% decline in Asia/Pacific & Europe;
Net loss per diluted share were $0.08, versus net income of $0.01 per diluted share a year ago;
Adjusted loss per diluted share were $0.07, versus adjusted earnings per diluted share of $0.05 a year ago;
Adjusted EBITDA of $0.8 million, compared to $1.9 million a year ago; and
Strong balance sheet with $17.4 million of cash and no debt.

* All comparisons are on a year over year basis and compare the second quarter of fiscal 2023 to the second quarter of fiscal 2022, unless otherwise noted.

“We reached a positive inflection point in the second quarter, delivering year-over-year revenue growth of

Read more...

Stemtech Anticipates Growth Rate In 2023 Will Exceed 2022

Stemtech today announced VISION 2023 concerning the exciting developments planned for the new year.
President and Chief Operating Officer, John W. Meyer says that “VISION 2023 for Stemtech was built on the foundations we enacted over the course of 2022.
“Our efforts were rewarded with a 20% growth of new Independent Business Partners (IBPs) and customers over FY 2021. We anticipate that this growth rate will actually be exceeded this year.
We introduced the powerful AdvanceOffice Mobile app for all of our distributors which enables them to operate their entire business via the app.
We launched a new proprietary blend named “CellectOne™”, a Rapid Renew Stem Cell Peptide Night Cream; we held our international conference in Cancun, Mexico this past December. Each one of these investments have generated exciting growth far beyond our expectations”
“For the upcoming fiscal year, we expect to increase our customer base as well as revenue. Much of this stems not only from our new product lines or increasing sales, but as much our human factor.
Our Field attendees came away from our Cancun event filled with excitement and new strategies to take to their customers, sharing the many opportunities of Stemtech.
We believe that sales will increase considerably in 2023

Read more...

2022: ibüümerang’s Biggest Year Yet

Throughout 2022, ibüümerang made company history time and time again: recognizing thousands of newly achieved ranks, such as the first Presidential Diamonds, the introduction of new and exciting travel and trade technologies, and events hosted in every corner of the world, including ibüümerang’s first European event.
The leadership in ibüümerang increased tenfold with all the new ranks broken;

two new Presidential Diamonds,
five new Black Diamonds,
nine new Blue Diamonds, and
30 new Diamond Ambassadors were created in 2022 alone.

With ibüümerang’s introduction of new events and avenues, paired with the incredible company momentum created, 2022 was a groundbreaking year that will lead to an even brighter future for years to come.
Take a speed run through the incredible ibüümerang events hosted in 2022 by checking out the official recap video below:

About ibüümerang: 
Officially launched on September 1, 2019, ibüümerang was founded on the vision and mission of giving back to others without expecting anything in return.
ibüümerang pioneered the concept of “you only earn when your customers save,” and supports the BüüM Foundation in providing an abundant life for every child on the planet.
For more information on ibüümerang and its top-tier leadership team, visit the company website at www.ibuumerang.com.
The post 2022: ibüümerang’s Biggest Year Yet appeared first on

Read more...

Mannatech Q3 Revenue Down 10 % To $35.5 Million

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2022.
Third Quarter End Results
Third quarter net sales for 2022 were $35.5 million, a decrease of $3.9 million, or 10.0%, as compared to $39.4 million in the third quarter of 2021. Our net sales declined 1.3% on a constant dollar basis (see Non-GAAP Measures, below) as foreign exchange decreased GAAP net sales by $3.4 million, mostly due to the decline of the Korean Won and Japanese Yen.
Third quarter operating income for 2022 was $1.4 million as compared to $3.3 million for the third quarter of 2021.
Net income was $1.2 million, or $0.61 per diluted share, for the third quarter of 2022, as compared to net income of $2.9 million, or $1.44 per diluted share, for the third quarter of 2021.
For the three months ended September 30, 2022, overall selling and administrative expenses decreased by $0.5 million to $6.7 million, as compared to $7.2 million for the same period in 2021. The decrease in selling and administrative expenses consisted of a $0.7 million decrease in payroll costs, and a $0.1 million decrease in warehouse costs, which was partially offset by a $0.3 million increase in marketing costs.
For the three months ended September 30, 2022, other operating costs increased by $0.1 million to $5.1 million, as compared to $5.0

Read more...

Tupperware Q3 Revenue Down 20% To $302 Million

Tupperware Brands Corporation (NYSE: TUP), a leading global consumer products company, today reported operating results for the third quarter ended September 24, 2022.
Third Quarter 2022 Financial Summary:

Net sales were $302.8 million, a decrease of 20% year over year (or 14% on a constant currency basis), compared to $376.9 million in the prior year period.
Gross profit was $196.6 million, or 64.9% of net sales, compared to $247.9 million, or 65.8% of net sales, in the prior year period
(Loss) income from continuing operations was $(3.8) million, compared to $60.4 million in the prior year period
Diluted (loss) earnings per share from continuing operations was $(0.09), compared to $1.14 in the prior year period
Adjusted diluted earnings per share (non-GAAP) from continuing operations was $0.14, compared to $1.19 in the period year
period
Adjusted EBITDA (non-GAAP, per debt covenant)1 from continuing operations was $29.9 million, compared to $77.7 million in the prior year period
Consolidated Net Leverage Ratio (non-GAAP) was 4.17, within the 4.5 debt covenant limit for the quarter

The Company continues to implement its Turnaround Plan; fixing the core, right sizing the business, divesting non-core assets and
opening new channels of distribution.
“While we are excited to expand the Tupperware ecosystem to have some of our products available at

Read more...

Nu Skin Q3 Revenue Down 16% To $537 Million

Nu Skin Enterprises, Inc. (NYSE: NUS) today announced third quarter 2022 results.
Executive Summary Q3 2022 vs. Prior-year Quarter:

Revenue: $537.8 million; (16)%
Earnings Per Share (EPS): $(0.51) or $0.47
Customers: 1,239,384; (11)%
Paid Affiliates: 243,276; (11)%
Sales Leaders: 49,824; (22)%

“Our third quarter results were impacted more than anticipated by worsening macro headwinds, including prolonged COVID-related disruptions in Mainland China, slowdown in South Korea, persistent global inflation and excessive foreign currency pressure,”
said Ryan Napierski, Nu Skin president and CEO.
“Despite the challenging macro environment, we further strengthened our position as the world’s leading beauty device system company by introducing our connected ageLOC® LumiSpa® iO.
This introduction, which continues in the fourth quarter, along with the expansion of ageLOC® Meta and Beauty Focus Collagen+ products and further advancement of our social commerce initiatives, helped us deliver constant-currency growth in four of our reporting segments.
The growth was led by Southeast Asia/Pacific and our tenth consecutive quarter of growth in our U.S. market. Japan and our Taiwan/Hong Kong segments grew in constant currency, with reported currency declines due to unfavorable foreign currency.
“We remain focused on Nu Vision 2025 for driving long-term growth and shareholder value as we continue executing against the core elements including the introduction of EmpowerMe,

Read more...